LESOPITRON DIHYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21ClN6.2ClH
Molecular Weight	393.742
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.ClC1=CN(CCCCN2CCN(CC2)C3=NC=CC=N3)N=C1

InChI

InChIKey=RGDLQJUAYQRGBC-UHFFFAOYSA-N

InChI=1S/C15H21ClN6.2ClH/c16-14-12-19-22(13-14)7-2-1-6-20-8-10-21(11-9-20)15-17-4-3-5-18-15;;/h3-5,12-13H,1-2,6-11H2;2*1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C15H21ClN6
Molecular Weight	320.82
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16032484 | https://adisinsight.springer.com/drugs/800001441 | Aronson, J.K. (2008) Meyler's Side Effects of Psychiatric Drugs, page 439, retrieved from: https://books.google.ru/books?id=AmYFTSO8jCkC

Lesopitron is a non-benzodiazepine anxiolytic with pre- and post-synaptic 5-HT1A agonist activity. Its structure is similar to that of buspirone. Lesopitron has negligible effects on alpha-adrenergic and dopaminergic receptors [162653], and was more potent than structurally-related 5-HT1A agonists in rat social interaction and marmoset anxiety models. It also countered benzodiazepine withdrawal-induced anxiety in rodents. The acute toxicity of lesopitron is low and it does not potentiate the effects of alcohol or barbiturates. Long-term usage led to reductions in plasma glucose, triglycerides, phospholipids and cholesterol. The most common adverse events associated with lesopitron were somnolence, headache, pharyngitis, and dyspepsia.

Approval Year

PubMed

Title	Date	PubMed
Effects of lesopitron on the central nervous system arising from its interaction with 5-HT1A receptors.	2004-10	15331910
Lesopitron (Esteve).	2001-02	16032484
Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.	2000-02	10676820
The effects of the novel anxiolytic drug lesopitron, a full and selective 5-HT1A receptor agonist, on pupil diameter and oral temperature in man: comparison with buspirone.	1999-12	10667616
Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat.	1999-04	10221756
The influence of 5-HT2 and 5-HT4 receptor antagonists to modify drug induced disinhibitory effects in the mouse light/dark test.	1997-11	9401775
Absorption, distribution and excretion of [14C]-Lesopitron after single and repeated administration in rats and dogs.	1997-01-01	9098842
Differential effects of haloperidol and two anxiolytic drugs, buspirone and lesopitron, on c-Fos expression in the rat striatum and nucleus accumbens.	1996-12-02	9117387
Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study.	1996-12	8959472

Patents

Sample Use Guides

In Vivo Use Guide

50 mg two times a day

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:14:33 GMT 2025` Edited by `admin` on `Mon Mar 31 18:14:33 GMT 2025`
Record UNII	4T5L4T8473
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

E-4424

Preferred Name

English

LESOPITRON DIHYDROCHLORIDE

Common Name

English

PYRIMIDINE, 2-(4-(4-(4-CHLORO-1H-PYRAZOL-1-YL)BUTYL)-1-PIPERAZINYL)-, HYDROCHLORIDE (1:2)

Systematic Name

English

PYRIMIDINE, 2-(4-(4-(4-CHLORO-1H-PYRAZOL-1-YL)BUTYL)-1-PIPERAZINYL)-, DIHYDROCHLORIDE

Common Name

English

LESOPITRON DIHYDROCHLORIDE [MI]

Common Name

English

Code System Code Type Description

PUBCHEM

60812